Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new opportunity in psychiatry and mental health medicinesThe September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory…
Aesthetic and beauty industry, underplayed by cosmeceuticals, shapes a soaring market worth $312.33B. Cosmeceuticals are known for their medical benefits beyond cosmetics and typically come in the forms of topical creams, serums, and lotions
Let’s unearth the secrets of cosmeceuticals like never before through engaging articles, illustrative infographics, regulatory updates, and much more
The…
Dedication, a go-getter attitude, and perseverance kept pushing PharmaShots to unlock new achievements now and then. Today, PharmaShots turns sixStarted as a news-delivering platform, PharmaShots has evolved over the years as a branding partner to several life sciences companiesWe appreciate your unwavering support that kept motivated us and making headway in our journey…
Shots: The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year. Top 20 Radiopharma Companies Based on Market Cap Shots: Integrating scintigraphy with…
Shots: Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
Intuitive, informative, and gripping, could be an articulate three-word summarization of our recent webinar on Competitive Intelligence. October 5th, 2023, the day PharmaShots, in association with Octavus Consulting, organized a webinar dedicated to competitive intelligence and navigated the nuances that go beyond the conventional definition of CI. Titled "Beyond the Horizon: Exploring Competitive Insights in…
Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMSPharmaShots presents…
Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the monthEnbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseasesPharmaShots…
Shots:David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regionsHe also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…

